Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.
July 21st 2021
In this Investigator Perspectives, Yi-Bin Chen, MD discusses the difference between acute and chronic graft versus host disease, the initial therapeutic management of these diseases, and the newly-approved agents for steroid-refractory disease. He also provides his insights regarding future directions and unmet needs for steroid-refractory GVHD.
July 20th 2021
An expert in hematology-oncology provides key insights into treatment considerations for patients with hepatocellular carcinoma and reviews safety and efficacy data from the phase 3 REFLECT Trial of lenvatinib for patients with unresectable disease.
June 30th 2021
Andrew J. Armstrong, MD, MSc, evaluates the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.
June 29th 2021
Robert J. Motzer, MD, gives a comprehensive background and analysis on the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus versus sunitinib in the treatment of advanced renal cell carcinoma.
June 28th 2021
Sara Hurvitz, MD, reviews the implications of the AMEERA-5 trial, a randomized, double-blind phase III study of amcenestrant + palbociclib vs letrozole + palbociclib in the treatment of ER+/HER2- advanced breast cancer.
June 25th 2021
Lori Wirth, MD provides an overview of differentiated thyroid cancer and reviews key data from the SELECT trial examining the use of lenvatinib.
April 20th 2021
Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.
March 29th 2021
Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).
March 29th 2021
Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.